Featured News

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a…

Researchers are collecting blood samples to help develop new diagnostics that may not require gluten ingestion or a biopsy to confirm the diagnosis. 

ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.

On August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001…

Researchers are collecting blood samples to learn more about the antigens that cause certain T cells to trigger intestinal damage in celiac disease patients. Complete a 30-minute study from home & be compensated $50 for your time.

ImmunsanT announces end of its global Phase 2 clinical trial for its Nexvax2 drug candidate. Early results indicate gluten-exposure protection similar to placebo.

If you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a clinical research study!

If you have celiac disease and currently have kidney stones, or have had kidney stones in the past, you may be eligible for a clinical research study!

Attention: Volunteers who have prior confirmation of celiac disease from blood work or a biopsy. If you meet the following criteria, you may qualify for a clinical research study of an investigational drug. Medical insurance is not necessary.

The CeliacShield Study is being conducted to assess the investigational drug latiglutenase and its ability to protect the small intestine of celiac disease patients from gluten exposure.